New Zealand markets closed

Genflow Biosciences plc (GENF.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
2.1750+0.0250 (+1.16%)
At close: 04:27PM BST

Genflow Biosciences plc

6 Heddon Street
London W1B 4BT
United Kingdom

Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Eric Jean Leire M.D., MBAFounder, CEO & Executive Director232.01kN/A1958
Dr. Cedric SzpirerHead of CMCN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Corporate governance

Genflow Biosciences plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.